NUF2 is a valuable prognostic biomarker to predict early recurrence of hepatocellular carcinoma after surgical resection.

Autor: Wang Y; Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore., Tan PY; Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore., Handoko YA; Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore., Sekar K; Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore., Shi M; Department of Hepatobiliary Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China., Xie C; Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China., Jiang XD; Department of Otorhinolaryngnology, Affiliated Hospital of Qingdao University, Qingdao, China., Dong QZ; Biological Specimen Bank, Affiliated Hospital of Qingdao University, Qingdao, China., Goh BKP; Department of Hepato-Pancreato-Biliary Surgery, Singapore General Hospital, Singapore., Ooi LL; Department of Hepato-Pancreato-Biliary Surgery, Singapore General Hospital, Singapore.; Division of Surgical Oncology, National Cancer Centre, Singapore., Gao Z; Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China., Hui KM; Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore.; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.; IMCB-NCCS Joint Programme, Institute of Molecular and Cell Biology, A*STAR, Singapore.; Cancer & Stem Cell Biology Programme, Duke-NUS Medical School, Singapore.
Jazyk: angličtina
Zdroj: International journal of cancer [Int J Cancer] 2019 Aug 01; Vol. 145 (3), pp. 662-670. Date of Electronic Publication: 2019 Feb 04.
DOI: 10.1002/ijc.32134
Abstrakt: Early tumor recurrence after curative surgical resection poses a great challenge to the clinical management of hepatocellular carcinoma (HCC). We conducted whole genome expression microarrays on 64 primary HCC tumors with clinically defined recurrence status and cross-referenced with RNA-seq data from 18 HCC tumors in the Cancer Genome Atlas project. We identified a 77-gene signature, which is significantly associated with early recurrent (ER) HCC tumors. This ER-associated signature shows significant enrichment in genes involved in cell cycle pathway. We performed receiver operating characteristic (ROC) analysis to evaluate the prognostic biomarker potential of these 77 genes and Pearson correlation analysis to identify 11 close clusters. The one gene with the best area under the ROC curve in each of the 11 clusters was selected for validation using reverse-transcription quantitative PCR in an independent cohort of 24 HCC tumors. NUF2 was identified to be the minimal biomarker sufficient to discriminate ER tumors from LR tumors. NUF2 in combination with liver cirrhosis could significantly improve the detection of ER tumors with an AUROC of 0.82 and 0.85 in the test and validation cohort, respectively. In conclusion, NUF2 in combination with liver cirrhosis is a promising prognostic biomarker for early HCC recurrence.
(© 2019 UICC.)
Databáze: MEDLINE